Table 2.
Clinical characteristics of prostate cancer patients according to AFPG
| Parameters | AFPG, according to optimal cut-off values | AFPG, according to clinical reference values | ||||||
|---|---|---|---|---|---|---|---|---|
| Grade 1 | Grade 2 | Grade 3 | P-value | Grade 1 | Grade 2 | Grade 3 | P-value | |
| Age (median, interquartile range), years | 78.5(72-82) | 76(68-79) | 75(66-79) | 0.005 | 76.5(62-79) | 76(65-82) | 76(68-79) | 0.908 |
| PSA (median, interquartile range), μg/L | 125.5(61.4-261.0) | 100.0(31.7-154.5) | 53.4(24.3-133.6) | <0.001 | 121(100-261) | 100(57.5-214) | 64.4(27.7-140.0) | 0.002 |
| Gleason Score (≤7/>7) | 17/41 | 75/105 | 129/95 | <0.001 | 0/6 | 31/61 | 190/174 | <0.001 |
| Metastasis (no/yes) | 21/37 | 83/97 | 154/70 | <0.001 | 0/6 | 42/50 | 216/148 | <0.001 |
| Risk Stratification (low-intermediate/high) | 3/55 | 14/166 | 30/194 | 0.025 | 0/6 | 4/88 | 43/321 | 0.077 |
Abbreviations: PSA: prostate-specific antigen; AFPG: pretreatment albumin and fibrinogen combined prognostic grade.